Aequs Shares Rise 6% as Company Lines Up ₹660 Crore Capex for FY27
Last Updated: 29th September 2026 - 11:27 am
Aequs shares rose as much as 6% in Monday’s trading session after the precision engineering and contract manufacturing company outlined a ₹660 crore capital expenditure plan for FY27.
The company is looking to put fresh capital into expanding its aerospace and consumer businesses as part of its growth plans through 2031. Alongside the planned capital expenditure, Aequs is preparing to raise ₹800 crore through debt.
Another round of fundraising is expected in FY28 as the company continues with its expansion plans.
₹650 Crore Equity Infusion Already Approved
The latest plans come after Aequs’ board approved an equity infusion of around ₹650 crore. The money will be used to increase capacity across the company’s aerospace and consumer businesses and support its borrowing programme.
The equity infusion will take place through warrants issued to the promoter group.
Of the approximately ₹650 crore issue, ₹325 crore will be paid upfront when the warrants are allotted. This represents 50% of the total issue size and is twice the regulatory minimum.
The remaining amount will be paid when the warrants are exercised.
Once the warrants are fully converted, the combined holding of Aequs’ promoter and promoter group will increase to 60.73% from the current 59.09%.
Drones and Defence Assemblies on the Agenda
Apart from expanding its existing aerospace and consumer operations, Aequs plans to enter the drones and defence assemblies segments.
The company’s planned ₹660 crore capital expenditure for FY27, proposed ₹800 crore debt raise and approved equity infusion form part of its broader expansion programme.
The developments brought the stock into focus on Monday, with Aequs shares gaining as much as 6% during the session.
- Flat ₹20 Brokerage
- Next-gen Trading
- Advanced Charting
- Actionable Ideas
Trending on 5paisa
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.